CAJ | 학술논문

目的：研究白细胞介素-1受体拮抗剂（IL-1Ra）及其编码基因（IL-1RN）多态性及与非小细胞肺癌的关系。探讨IL-1Ra应用于临床非小细胞肺癌诊断的可行性。方法采用PCR技术对95例非小细胞肺癌患者及130例健康对照的IL-1RN 基因多态性进行分析。同时采用ELISA方法对95例非小细胞肺癌患者及130例健康对照组血清中CYFRA21-1、CEA、SCC以及IL-1Ra的含量进行检测分析。对其中60例非小细胞肺癌患者癌组织及周边正常肺组织中 IL-1Ra 的含量进行测定。结果 IL-1RN*2在鳞癌患者与腺癌患者之间无显著性差异。非小细胞肺癌患者癌组织中IL-1Ra的含量显著高于正常肺组织，非小细胞肺癌患者血清中IL-1Ra的含量显著高于健康对照（P＜0.01）。其中，鳞癌患者组织中IL-1Ra含量为（302700±41250）pg/g，血清中IL-1Ra含量为（488.9±62.2）pg/ml。鳞癌患者组织及血清中IL-1Ra含量显著高于腺癌（P＜0.01）。IL-1Ra 与 CEA、SCC 对非小细胞肺癌诊断的敏感度和特异度接近。结论非小细胞肺癌患者尤其是鳞癌患者IL-1Ra浓度显著增高，提示IL-1Ra有可能作为非小细胞肺癌，尤其是鳞癌临床诊断的检测指标。
목적：연구백세포개소-1수체길항제（IL-1Ra）급기편마기인（IL-1RN）다태성급여비소세포폐암적관계。탐토IL-1Ra응용우림상비소세포폐암진단적가행성。방법채용PCR기술대95례비소세포폐암환자급130례건강대조적IL-1RN 기인다태성진행분석。동시채용ELISA방법대95례비소세포폐암환자급130례건강대조조혈청중CYFRA21-1、CEA、SCC이급IL-1Ra적함량진행검측분석。대기중60례비소세포폐암환자암조직급주변정상폐조직중 IL-1Ra 적함량진행측정。결과 IL-1RN*2재린암환자여선암환자지간무현저성차이。비소세포폐암환자암조직중IL-1Ra적함량현저고우정상폐조직，비소세포폐암환자혈청중IL-1Ra적함량현저고우건강대조（P＜0.01）。기중，린암환자조직중IL-1Ra함량위（302700±41250）pg/g，혈청중IL-1Ra함량위（488.9±62.2）pg/ml。린암환자조직급혈청중IL-1Ra함량현저고우선암（P＜0.01）。IL-1Ra 여 CEA、SCC 대비소세포폐암진단적민감도화특이도접근。결론비소세포폐암환자우기시린암환자IL-1Ra농도현저증고，제시IL-1Ra유가능작위비소세포폐암，우기시린암림상진단적검측지표。
Objective The level of interleukin (IL)-1 receptor antagonist (IL-1Ra) and interleukin-1 receptor antagonist gene(IL-1RN) polymorphism were investigated to analyze the relationship between the concentrations of IL-1Ra, IL-1RN and non-small cell lung cancer (NSCLC). The feasibility of diagnosis to NSCLC were evaluated. Methods PCR was used to detect DNA samples from 95 NSCLC patients and 130 health controls for the analysis of the gene polymorphism. Serum concentrations of CYFRA21-1, CEA, SCC and IL-1Ra in 95 NSCLC patients and 130 health controls were also determined by ELISA. Tissue concentrations of IL-1Ra in 60 primary NSCLC patients were detected. Results No significant difference of IL-1RN*2 were found between patients with squamous cell carcinoma and adenocarcinomas. The tissue concentrations of IL-1Ra were significantly higher in NSCLC tissue than those in normal lung tissue(P<0.01). The serum concentrations of IL-1Ra were significantly higher in NSCLC patients than those in control. The tissue and serum concentrations of IL-1Ra were significantly higher in subjects with squamous cell carcinoma than those with adenocarcinomas(P<0.01). The tissue and serum concentrations of IL-1Ra in patients with squamous cell carcinoma were (302 700±41 250)pg/g and (488.9±62.2)pg/ml respectively. The specificity and the sensitivity of IL-1Ra was close to that of CEA or SCC. Conclusion The concentrations of IL-1Ra were significantly higher in patients with NSCLC, especially in patients with squamous cell carcinoma. It may be as a potential marker of clinical test.